Top ▲

C-type lectin domain family 12 member A

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 3081

Nomenclature: C-type lectin domain family 12 member A

Systematic Nomenclature: CD371

Family: C-type lectin-like receptors (CLRs)

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 265 12p13.31 CLEC12A C-type lectin domain family 12 member A
Mouse 1 267 6 F3 Clec12a C-type lectin domain family 12, member a
Rat 1 269 4q42 Clec12a C-type lectin domain family 12, member A
Previous and Unofficial Names Click here for help
C-type lectin domain family 12, member A | C-type lectin domain family 12, member a | C-type lectin domain family 12 | CLL-1 | dendritic cell-associated lectin 2 | DCAL-2 | myeloid inhibitory C-type lectin-like receptor | MICL
Database Links Click here for help
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
tepoditamab Peptide Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Binding 8.5 pKd 5
pKd 8.5 (Kd 3x10-9 M) [5]
Description: Binding affinity for hCLEC12A determined by surface plasmon resonance.
Immunopharmacology Comments
The CLEC12A protein is a negative regulator of granulocyte and monocyte function [2,4]. In vitro analyses indicate that CLEC12A may not act as a bona fide carbohydrate-sensitive pattern recognition receptor [7]. Studies using human cells suggests that CLEC12A synergises with signals from other receptors to facilitate dendritic cell (DC) responses, an action that modulates functions including DC migration and T cell activation.
CLEC12A is recognised as a novel prognostic and therapeutic marker of acute myeloid leukemia (AML) [1,6]. It is not expressed on normal early hematopoietic progenitors (including hematopoietic stem cells), so offers a highly selective target for AML immuno-oncology. One agent in the pharma pipeline is tepoditamab [5], a bispecific monoclonal antibody that binds both CLEC12A (on AML cells) and CD3 (on cytotoxic T cells), and which is expected to eradicate both AML blasts and their progenitors, to provide a more effective outcome for AML patients.
Cell Type Associations
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   classical monocyte (CL:0000860)
References:  4
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   granulocyte (CL:0000094)
References:  4
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
plasmacytoid dendritic cell (CL:0000784)
dendritic cell, human (CL:0001056)
plasmacytoid dendritic cell, human (CL:0001058)
Comment:  Expressed on mouse and human dendritic cell subsets.
References:  3
Immuno Process Associations
Immuno Process:  Cellular signalling
Immuno Process:  Inflammation
Immuno Process:  Immune regulation
General Comments
The CLEC12A protein is a myeloid cell surface antigen that is regarded as a marker of acute myeloid leukemia (AML) stem cells [1,6], and as a novel target for the treatment of AML.


Show »

1. Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA et al.. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res, 64 (22): 8443-50. [PMID:15548716]

2. Han Y, Zhang M, Li N, Chen T, Zhang Y, Wan T, Cao X. (2004) KLRL1, a novel killer cell lectinlike receptor, inhibits natural killer cell cytotoxicity. Blood, 104 (9): 2858-66. [PMID:15238421]

3. Lahoud MH, Proietto AI, Ahmet F, Kitsoulis S, Eidsmo L, Wu L, Sathe P, Pietersz S, Chang HW, Walker ID et al.. (2009) The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol, 182 (12): 7587-94. [PMID:19494282]

4. Marshall AS, Willment JA, Lin HH, Williams DL, Gordon S, Brown GD. (2004) Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem, 279 (15): 14792-802. [PMID:14739280]

5. Van Loo PF, Doornbos R, Dolstra H, Shamsili S, Bakker L. (2015) Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML. Blood, 126 (23): 325.

6. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, 110 (7): 2659-66. [PMID:17609428]

7. Weis WI, Taylor ME, Drickamer K. (1998) The C-type lectin superfamily in the immune system. Immunol Rev, 163: 19-34. [PMID:9700499]

How to cite this page

C-type lectin-like receptors (CLRs): C-type lectin domain family 12 member A. Last modified on 02/04/2019. Accessed on 14/06/2024. IUPHAR/BPS Guide to PHARMACOLOGY,